Intelligent Bio Solutions Inc. (INBS)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $5.84M
Last updated: Nov 17, 2026 at 11:03 AM ET
Intelligent Bio Solutions Inc. (INBS) Financials: Revenue, Profit and Cash Flow
Intelligent Bio Solutions reported revenue of $4.22M for the fiscal year ended Jun 30, 2026, up 38.1% from the year before. That year, net income was -$12.47M with a net margin of -295.8%, operating cash flow was -$11.93M and free cash flow was -$12.05M. The quarter ended Sep 30, 2026 had revenue of $1.39M and net income of -$2.67M.
Revenue and Margins
Over the 6 years to Jun 2026, revenue grew from $188.74K, a compound annual rate of 67.8%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Jun 2026 | $4.22M | +38.1% | 48.6% | -299.1% | -295.8% |
| Jun 2025 | $3.05M | -1.9% | 40.8% | -349.8% | -347.4% |
| Jun 2024 | $3.11M | +147.6% | 45.8% | -330.5% | -327.5% |
| Jun 2023 | $1.26M | N/A | 26.0% | -1002.1% | -848.5% |
| Jun 2022 | $0 | -100.0% | N/A | N/A | N/A |
| Jun 2021 | $1.98M | +949.3% | 100.0% | -281.4% | -356.5% |
| Jun 2020 | $188.74K | N/A | 100.0% | -1513.7% | -1691.7% |
| Jun 2019 | $0 | N/A | N/A | N/A | N/A |
| Jun 2018 | N/A | N/A | N/A | N/A | N/A |
| Jun 2017 | N/A | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Jun 2026, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.22M | $3.05M | $3.11M | $1.26M | $0 | $1.98M | $188.74K | $0 | N/A | N/A |
| Cost of revenue | $2.17M | $1.81M | $1.69M | $930.20K | $0 | $0 | $0 | N/A | N/A | N/A |
| Gross profit | $2.05M | $1.25M | $1.43M | $326.67K | $0 | $1.98M | $188.74K | N/A | N/A | N/A |
| Research and development | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $3.18M | $2.53M | $0 |
| Operating income | -$12.61M | -$10.68M | -$10.28M | -$12.60M | -$8.34M | -$5.57M | -$2.86M | -$6.73M | -$4.60M | -$173.00K |
| Net income | -$12.47M | -$10.60M | -$10.19M | -$10.66M | -$8.33M | -$7.06M | -$3.19M | -$7.34M | -$5.02M | -$340.00K |
| EBITDA | -$11.40M | -$9.47M | -$8.90M | -$9.48M | N/A | N/A | -$2.86M | -$6.67M | -$417.00K | -$151.00K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.39M | $1.15M | $1.06M | $896.77K | $1.11M | $843.88K | $728.87K | $607.49K | $872.29K | $727.82K | $823.80K | $764.06K |
| Gross profit | $758.00K | $536.58K | $535.38K | $459.74K | $518.29K | $335.58K | $341.37K | $223.11K | $346.80K | $815.56K | $178.49K | $199.25K |
| Operating income | -$2.68M | -$4.03M | -$2.95M | -$2.64M | -$3.00M | -$3.13M | -$2.56M | -$2.26M | -$2.73M | -$2.81M | -$2.95M | -$1.99M |
| Net income | -$2.67M | -$3.92M | -$2.87M | -$2.69M | -$2.99M | -$3.10M | -$2.55M | -$2.26M | -$2.69M | -$2.80M | -$2.99M | -$1.98M |
Balance Sheet
As of Jun 2026, cash and equivalents exceeded short-term debt of $0 by $3.99M.
Annual
| Line item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $11.94M | $8.25M | $13.78M | $10.35M | $12.35M | $21.86M | $2.48M | $2.33M | $2.50M | $667.23K |
| Current assets | $7.10M | $4.14M | $8.53M | $3.86M | $10.87M | $18.21M | $2.34M | $2.33M | $2.50M | $667.23K |
| Cash and equivalents | $3.99M | $1.02M | $6.30M | $1.54M | $8.24M | $12.57M | $427.27K | $197.94K | $418.42K | $56.03K |
| Total liabilities | $6.65M | $5.44M | $5.60M | $6.67M | $5.81M | $6.85M | $7.69M | $6.31M | $5.56M | $6.58M |
| Short-term debt | $0 | $197.15K | $515.28K | $353.21K | $0 | $137.81K | $5.13M | $5.13M | $4.84M | $3.53M |
| Long-term debt | N/A | N/A | N/A | $402.86K | $0 | N/A | N/A | N/A | N/A | N/A |
| Shareholder equity | $5.51M | $3.00M | $8.33M | $3.80M | $6.62M | $15.06M | -$5.19M | -$4.62M | -$4.38M | -$5.91M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $13.62M | $11.94M | $14.86M | $17.65M | $10.04M | $8.25M | $9.58M | $8.68M | $11.73M | $13.78M | $17.04M | $8.83M |
| Total liabilities | $6.27M | $6.65M | $6.11M | $6.76M | $6.61M | $5.44M | $4.64M | $4.48M | $5.78M | $5.60M | $6.04M | $5.67M |
| Cash and equivalents | $5.93M | $3.99M | $6.86M | $740.37K | $1.66M | $1.02M | $2.81M | $2.24M | $3.99M | $6.30M | $9.40M | $1.12M |
| Shareholder equity | $7.58M | $5.51M | $8.96M | $11.09M | $3.62M | $3.00M | $5.11M | $4.37M | $6.10M | $8.33M | $11.13M | $3.28M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Jun 2026.
Annual
| Line item | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11.93M | -$9.68M | -$9.57M | -$7.38M | -$3.36M | -$11.30M | -$498.62K | -$5.58M | -$5.38M | -$243.89K |
| Capital expenditures | $125.73K | $231.84K | $221.43K | $0 | $380.22K | $3 | $380.22K | $380.22K | $0 | $0 |
| Free cash flow | -$12.05M | -$9.91M | -$9.79M | -$7.38M | -$3.74M | -$11.30M | -$878.84K | -$5.96M | -$5.38M | -$243.89K |
| Share repurchases | N/A | N/A | N/A | $518.91K | $0 | $2.00M | N/A | N/A | N/A | N/A |
| Investing cash flow | -$85.57K | -$231.84K | -$221.43K | -$694.14K | -$880.22K | $0 | -$14.00K | -$14.00K | N/A | N/A |
| Financing cash flow | $14.98M | $4.60M | $14.56M | $1.44M | $0 | $23.40M | $733.86K | $5.32M | $5.18M | $299.92K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.75M | -$3.18M | -$4.33M | -$1.57M | -$2.85M | -$2.21M | -$2.76M | -$2.32M | -$2.39M | -$2.94M | -$2.45M | -$2.87M |
| Capital expenditures | $0 | N/A | $12.90K | $68.23K | $70.40K | $208.52K | $14.38K | $8.94K | $0 | $167.31K | $2.55K | $56.67K |
| Free cash flow | -$2.75M | N/A | -$4.34M | -$1.64M | -$2.92M | -$2.42M | -$2.77M | -$2.33M | -$2.39M | -$3.11M | -$2.45M | -$2.93M |
Frequently Asked Questions About INBS
What is Intelligent Bio Solutions' annual revenue?
Intelligent Bio Solutions reported revenue of $4.22M for the fiscal year ended Jun 30, 2026.
How fast is Intelligent Bio Solutions' revenue growing?
Revenue was up 38.1% for the fiscal year ended Jun 30, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was 49.7%.
Is Intelligent Bio Solutions profitable?
No. Intelligent Bio Solutions reported net income of -$12.47M for the fiscal year ended Jun 30, 2026, with a net margin of -295.8%.
How much free cash flow does INBS generate?
For the fiscal year ended Jun 30, 2026, operating cash flow of -$11.93M minus capital expenditures of $125.73K produced free cash flow of -$12.05M.
How much debt does Intelligent Bio Solutions have?
The balance sheet dated Jun 30, 2026 reported short-term debt of $0 and cash and equivalents of $3.99M.
INBS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors